Dear Shareholders, After wrapping up our three-part series on autoimmune pulmonary alveolar proteinosis (aPAP) that provided perspectives on the disease from a physician, a patient, and an advocate, we thought… read more →
Dear Shareholders, Our last two blog entries focused on the rare lung disease autoimmune pulmonary alveolar proteinosis (aPAP). Treatment of aPAP is the focus of our investigational drug candidate, Molgradex,… read more →
Dear Shareholders, The last entry we posted was written by guest blogger, Dr. Bruce Trapnell. He provided a physician’s perspective on autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung disease… read more →
Special Meeting To Be Held on April 21, 2017 SAN DIEGO, CA and AUSTIN, TX – March 16, 2017 – Mast Therapeutics, Inc. (NYSE MKT: MSTX) announced today it has… read more →
Proposed Merger Creates Specialty Pharmaceutical Company with Three Clinical-Stage Inhaled Product Candidates for Serious and Life-Threatening Diseases Conference Call Scheduled for Monday, January 9 at 8:30 a.m. ET / 5:30… read more →
Austin, Texas – November 2, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced the company has appointed David L. Lowrance, CPA, as… read more →
Strengthens pipeline serving patients with rare respiratory diseases Austin, Texas – July 18, 2016 – Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced the… read more →
Adds two orphan respiratory drugs to its growing pipeline Austin, Texas – June 21, 2016 Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced that… read more →
New York City – June 9, 2016 Savara Pharmaceuticals, an emerging specialty pharmaceutical company focused on rare respiratory diseases, today announced that the company will present at the Jefferies 2016… read more →
Savara’s phase II/III clinical trial of lead drug candidate Molgradex® for patients with pulmonary alveolar proteinosis (PAP) has included its first patient. The patient has been dosed with Savara’s proprietary,… read more →
